Department of Pediatrics, Shengjing Hospital of China Medical University, Shenyang 110004, China.
Zhongguo Dang Dai Er Ke Za Zhi. 2022 Jan 15;24(1):108-114. doi: 10.7499/j.issn.1008-8830.2109166.
Bronchopulmonary dysplasia (BPD) is a chronic lung disease due to impaired pulmonary development and is one of the main causes of respiratory failure in preterm infants. Preterm infants with BPD have significantly higher complication and mortality rates than those without BPD. At present, comprehensive management is the main intervention method for BPD, including reasonable respiratory and circulatory support, appropriate enteral nutrition and parenteral nutrition, application of caffeine/glucocorticoids/surfactants, and out-of-hospital management after discharge. The continuous advances in stem cell medicine in recent years provide new ideas for the treatment of BPD. Various pre-clinical trials have confirmed that stem cell therapy can effectively prevent lung injury and promote lung growth and damage repair. This article performs a comprehensive analysis of the mechanism of mesenchymal stem cells in the treatment of BPD, so as to provide a basis for clinical applications.
支气管肺发育不良(BPD)是一种由肺发育受损引起的慢性肺部疾病,是早产儿呼吸衰竭的主要原因之一。患有 BPD 的早产儿比没有 BPD 的早产儿有更高的并发症和死亡率。目前,综合管理是 BPD 的主要干预方法,包括合理的呼吸和循环支持、适当的肠内和肠外营养、咖啡因/糖皮质激素/表面活性剂的应用,以及出院后的院外管理。近年来,干细胞医学的不断进步为 BPD 的治疗提供了新的思路。各种临床前试验已经证实,干细胞治疗可以有效预防肺损伤,促进肺生长和损伤修复。本文对间充质干细胞在治疗 BPD 中的作用机制进行了全面分析,以期为临床应用提供依据。
Zhongguo Dang Dai Er Ke Za Zhi. 2022-1-15
Pediatr Int. 2019-10
Neonatology. 2015
Zhongguo Dang Dai Er Ke Za Zhi. 2018-7
Am J Stem Cells. 2025-6-15
Front Med (Lausanne). 2021-6-15
Children (Basel). 2021-4-13
Int J Mol Sci. 2021-2-27